Zydus Enters Global Biologics CDMO Market
Slice of Healthcare Team
Jun 06, 2025
Key highlights
- Zydus acquires U.S.-based CMC facilities from Agenus for $125M
- Strategic move expands Zydus' footprint into the global biologics CDMO market
- Acquisition includes facilities in Emeryville and Berkeley, California
- Zydus gains exclusive manufacturing rights for Agenus' Phase-3 IO products
- CDMO business to function independently with job creation plans
Notable Quote
“ The acquisition will give Zydus a strategic foothold in the U.S. for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry. ”
Dr. Sharvil Patel, Managing Director at Zydus Lifesciences Ltd
Why This Matters
Zydus’ acquisition of Agenus Inc.’s biologics CMC facilities signifies a major step into the global biologics CDMO space, one of the fastest-growing sectors in the pharmaceutical industry. With biologics increasingly central to modern therapeutic strategies and a rising number of biotech startups lacking internal manufacturing capabilities, the demand for CDMO services is rapidly escalating. By establishing a strong manufacturing presence in California—a global epicenter for biotech innovation—Zydus not only accelerates its global expansion but also positions itself as a full-spectrum biologics solution provider. This deal enhances its ability to support innovation, create local jobs, and deliver scalable, high-quality biomanufacturing to partners worldwide.
